Effects of Long-Term Pravastatin Treatment on Serum and Urinary Monocyte Chemoattractant Protein-1 Levels and Renal Function in Type 2 Diabetic Patients with Normoalbuminuria

REFERENCES

• Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, et al. Risk factor for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 823–828
   PubMed Web of Science ®Google Scholar
• Betteridge DJ. Long-term risk reduction: Who needs treatment?. Diabetes Res. Clin. Pract. 2005; 68S2: S15–S22
   Google Scholar
• Danesh FR, Kanwar YS. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy. FASEB J. 2004; 18: 805–815
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J. Am. Coll. Cardiol. 2005; 46: 1425–1433
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomized placebo-controlled trial. Lancet. 2003; 360: 2005–2016
   Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet 2004; 364: 685–696
   PubMed Web of Science ®Google Scholar
• Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1452–1458
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM. PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study. JAMA 2001; 286: 64–70
   PubMed Web of Science ®Google Scholar
• Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001; 103: 1933–1935
   PubMed Web of Science ®Google Scholar
• Reape TJ, Groot PHE. Chemokines and atherosclerosis. Atherosclerosis. 1999; 147: 213–225
   PubMed Web of Science ®Google Scholar
• Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: Enhanced biological insights. Atherosclerosis. 2002; 160: 91–102
   PubMed Web of Science ®Google Scholar
• Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS. Human endothelium as a source of multifunctional cytokines: Molecular regulation and possible role in human disease. J. Interferon. Cytokine. Res. 1999; 19: 91–104
   PubMed Web of Science ®Google Scholar
• Rovin BH, Yoshimura T, Tan L. Cytokine-induced production of monocyte chemoattractant protein-1 by cultured human mesangial cells. J. Immunol. 1992; 148: 2148–2153
   PubMed Web of Science ®Google Scholar
• Prodjosudjadi W, Gerritsma JS, Klar-Mohamad N, Gerritsen AF, Bruijn JA, Daha MR, et al. Production and cytokine-mediated regulation of monocyte chemoattractant protein-1 by human proximal tubular epithelial cells. Kidney Int. 1995; 48: 1477–1486
   PubMed Web of Science ®Google Scholar
• Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, et al. RANTES and MCP-1 play an important role in the inflammatory phase of crescentic nephritis but only MCP-1 is involved in crescent formation and interstitial fibrosis. J. Exp. Med. 1997; 185: 1371–1380
   PubMed Web of Science ®Google Scholar
• Wada T, Furuichi K, Sakai N, Iwata Y, Yoshitomo K, Shimizu M, et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int. 2000; 58: 1492–1499
   PubMed Web of Science ®Google Scholar
• Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J. Diabetes Complications 2003; 17: 11–15
   PubMed Web of Science ®Google Scholar
• Morii T, Fujita H, Narita T, Koshimura J, Shimotomai T, Fujishima H, et al. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal disease. Ren. Fail. 2003; 25: 439–444
   PubMed Web of Science ®Google Scholar
• Koshimura J, Narita T, Sasaki H, Hosoba M, Yoshioka N, Shimotomai T, et al. Urinary excretion of transferrin and orosomucoid are increased after acute protein loading in healthy subjects. Nephron Clin. Pract. 2005; 100: c33–c37
   PubMedGoogle Scholar
• Rovin BH, Tan LC. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int. 1993; 43: 218–225
   PubMedGoogle Scholar
• Coritsidis G, Rifici V, Gupta S, Rie J, Shan ZH, Neugarten J, et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int. 1991; 39: 858–866
   PubMed Web of Science ®Google Scholar
• Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D. Interactions of LDL and modified LDL with mesangial cells and matrix. Kidney Int. 1992; 41: 1161–1169
   PubMedGoogle Scholar
• Sorof J, Berne C, Siewert-Delle A, Jorgensen L, Sager P. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2006; 72: 81–87
   PubMed Web of Science ®Google Scholar
• Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J. Am. Soc. Nephrol. 2003; 14: 1605–1613
   PubMed Web of Science ®Google Scholar
• Feng L, Matsumoto C, Schwartz A, Schmidt AM, Stern DM, Pile-Spellman J. Chronic vascular inflammation in patients with type 2 diabetes. Diabetes Care 2005; 28: 379–384
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003; 107: 690–695
   PubMed Web of Science ®Google Scholar
• Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto J, de P, Morrow DA, et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J. Am. Coll. Cardiol. 2004; 44: 1812–1818
   PubMed Web of Science ®Google Scholar